Bendamustine: Safety and efficacy in the management of indolent non-Hodgkins lymphoma

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 145-156

  Tageja, Nishant ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bendamustine; Follicular lymphoma; Indolent non Hodgkin's lymphoma; Lympho proliferative disorders; Novel therapy

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 1A2; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IDARUBICIN; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER CELL DESTRUCTION; CLINICAL EFFECTIVENESS; CONSTIPATION; DIARRHEA; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHYSICAL CHEMISTRY; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA;

EID: 79958034401     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6085     Document Type: Review

References (72)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481-8.
3. Groves FD, Linet MA, Travis LB, Devesa SS. Cancer surveillance series: non Hodgkin's lymphoma: incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;19:1240-51.
4. Keegan THM, McClure LA, Foran JM, Clarke CA. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population- based study. J Clin Oncol. 2009;27:3044-51.
5. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447-52.
6. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advancedstage non-Hodgkin lymphoma: a randomized controlled trial. Lancet. 2003; 362:516-22
7. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-9.
8. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-9.
9. Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol. 2008;26: 211-7.
10. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.
11. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cylophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-32.
12. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the National Lympho Care Study. J Clin Oncol. 2009;27:1202-8.
13. Stolz C, Schuler M. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leuk Lymphoma. 2009 Jun;50(6):873-5.
14. Hagenbeek A, Eghbali H, Monfardini S, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol. 2006;24(10): 1590-6.
15. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomabtiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non- Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262-9.
16. Ozegowski W, Krebs D. IMET 3393, (-[1-Methyl-5-bis-(β-chloroethyl)- amino-benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds [in German]. Zbl Pharm. 1971;110:1013-9.
17. Cephalon, Inc. Treanda (bendamustine hydrochloride for injection) for intravenous infusion: US prescribing information. Cephalon, Inc: Frazer (PA), 2008 Oct.
18. Cephalon. Cephalon receives FDA approval for Treanda to treat patients with relapsed indolent non-Hodgkin's lymphoma [media release]. 2008 Oct 31 [online]. Available from URL: http://www.cephalon.com/media/news-releases/.
19. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002 Aug;29(4 Suppl 13):4-11.
20. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309-17.
21. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393, and 3943. Biochim Biophys Acta. 1972;287:386-9.
22. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs. 1996;7:415-21.
23. Leoni LM, Bailey B, Reifert J. SDX-105 (Bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood. 2003; 102:640a; abstr 2363.
24. Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica. 2001;86:485-93.
25. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol. 2002;29:12-4.
26. Kanekal S, Crain B, Elliott G. SDX-105 (TreandaTM) enhances the tumor growth inhibitory effect of rituximab in Daudi lymphoma xenografts. Blood. 2004;104:229b. abstr 4580.
27. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDECC2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica. 2002;87:33-43.
28. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs. 2007;18:587-95.
29. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumors. Br J Cancer. 2007;96:1692-8.
30. Matthias M, Preiss R, Sohr R, et al. Pharmacokinetics of bendamustine in patients with malignant tumors [abstract no. 1476]. 31st Annual Meeting of the American Society of Clinical 2008 Nov 4]. Oncology. 1995;14:458. Los Angeles (CA).
31. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol. 2007;59:759-70.
32. Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Disp. 2005;33:984-92.
33. Höffken K, Merkle K, Schönfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II study. J Cancer Res Clin Oncol. 1998;124:627-32.
34. Schöffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine: A phase I study in patients with advanced progresive solid tumors. Ann Oncol. 2000;11:729-34.
35. Schöffski P, Hagedorn T, Grünwald V, et al. Repeated administration of short infusions of bendamustine: A phase I study in patients with advanced progressive solid tumors. J Cancer Res Clin Oncol. 2000;126:41-7.
36. Ogura M, Uchida T, Taniwaki M, et al. Japanese Bendamustine Lymphoma Study Group. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010 Sep;101(9):2054-8. doi: 10.1111/j.1349-7006.2010.01633.x.
37. Owen JS, Melhem M, D'Andrea D, et al. Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin's lymphoma (NHL). Pharmacol Ther. 2008;83(Suppl 1):S54-5.
38. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphoma. Anticancer Drugs. 2001;12:725-9.
39. Bremer K. High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol. 2002;128:603-9.
40. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204-10.
41. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2009 Nov 4.
42. Ohmachi K, Ando K, Ogura M, et al. Japanese Bendamustine Lymphoma Study Group. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006. 2010.01635.x.
43. Ruffert K, Jann H, Syrbe G, et al. Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin's lymphoma. Z Klin Med. 1989;44:671-4.
44. Blumenstengel K, Fricke HJ, Kath R, et al. Bendamustine (B), vincristine (O), prednisone (P) in relapsed and refractory low grade non-Hodgkin's lymphoma (NHL) [abstract]. Ann Hematol. 1998;77(Suppl 11):S149.
45. Herold M, Schulze A, Mantovani L, et al. BOP versus COP in advanced low-grade non-Hodgkin's lymphoma-results of a randomized multicenter trial [abstract]. Ann Oncol. 1999;10(Suppl 3):125.
46. Kath R, Höffken K, Merkle K. Prevention of immunological complications in bendamustine treatment [abstract]. Onkologie. 2000;23:171.
47. Heck HK, Preiss JM, Schmidt P. Bendamustine (B) and mitoxantrone (M) in the treatment of low grade non-Hodgkin's lymphoma (NHL) [abstract]. J Cancer Res Clin Oncol. 1998;124(Suppl):R147.
48. Kahl C, Herold M, Höffkes H, et al. Bendamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high grade non- Hodgkin's lymphoma. Onkologie. 1997;20:406-8.
49. König U, Junghass C, Decker S, et al. Response of refractory and relapsed low grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride-containing regimen [abstract]. Ann Oncol. 1999;10(Suppl 3):132.
50. Ruffert K. Therapy of low grade non-Hodgkin's lymphoma (NHL) with bendamustineand oral etoposide [abstract]. Ann Oncol. 1999;10(Suppl 3):125.
51. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol. 2006;132:105-12.
52. Königsmann M, Knauf W, Herold M, et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma-a multicenter phase I/II trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma. 2004;45:1821-7.
53. Weide R, Heymanns J, Köppler H. Successful treatment of alkylating agent resistant low grade B-cell non Hodgkin's lymphomas with bendamustine/ mitoxantrone/rituximab (BMR) [abstract]. Onkologie. 1999;22(Suppl 1):644.
54. Weide R, Heymanns J, Gores A, et al. Bendamustine, mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma. 2002;43:327-31.
55. Weide R, Pandorf A, Heymanns J, et al. Bendamustine/Mitoxantrone/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma. 2004;45:2445-9.
56. Weide R, Hess G, Köppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A mul-ticenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma. 2007;48:1299-306.
57. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383-9.
58. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4473-9.
59. Rummel MJ, von Grünhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first line treatment of patients with indolent and mantle cell lymphomas-first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Blood. 2007;110:385.
60. Kirchner HH, Gaede B, Steinhauer EU, et al. Chemoimmuno-therapy with Fludarabine, Bendamustine and Rituximab for relapsed low grade malignant non-Hodgkin's lymphoma [abstract]. Blood. 2001;98:568.
61. Moosmann P, Heizmann M, Kotrubczik N, Wernli M, Bargetzi M. Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. 2009 Oct 1. [Epub ahead of print].
62. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011 Mar 10;117(10):2807-12. Epub 2011 Jan 14.
63. Matous J, Letzer J, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): dose-finding results of the VERTICAL study. J Clin Oncol. 2009;27:446s. Abstract 8550.
64. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory folicular lymphoma: encouraging activity in the phase 2 VERTICAL study. Blood. 2009;114:384-5. Abstract 933.
65. Weide R. Bendamustine HCL for the treatment of relapsed indolent non- Hodgkin's lymphoma. Ther Clin Risk Manag. 2008 Aug;4(4):727-32.
66. NCT00864942. http://clinicaltrials.gov/ct2/show/NCT00864942?term=bendamustine&rank=9.
67. NCT00987493. http://clinicaltrials.gov/ct2/show/NCT00987493?term=bendamustine&rank=38.
68. NCT00880815. http://clinicaltrials.gov/ct2/show/NCT00880815?term=bendamustine&rank=4.
69. NCT00901927. http://clinicaltrials.gov/ct2/show/NCT00901927?term=bendamustine&rank=2.
70. NCT00877006. http://clinicaltrials.gov/ct2/show/NCT00877006?term=bendamustine&rank=33.
71. Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol. 2010 Aug;66(3):413-23. Epub 2010 Apr 8. Review.
72. Cheson BD, Wendtner CM, Pieper A, Dreyling M, Friedberg J, Hoelzer D et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non- Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):21-7.